In a legal clash of point-of-care ultrasound (POCUS) titans, Fujifilm Sonosite has filed litigation against Butterfly Network charging that company with violating its patents for acquiring ultrasound images at the point of care with handheld scanners.
In a March 9 press release, Fujifilm Sonosite said it filed the lawsuit in the U.S. District Court for the District of Delaware, charging Butterfly with violating seven patents it holds pertaining to "fundamental technology" for acquiring ultrasound with POCUS systems.
The patents cover a variety of aspects of point-of-care ultrasound, including using a probe that is coupled to a mobile device, elements of a handheld scanner's graphical user interface, and technologies related to the processing and display of ultrasound images. The patents are U.S. Patent Nos. 7,169,108; 7,867,168; 8,128,050; 8,861,822; 9,538,985; 6,901,157; and 8,360,981.
Fujifilm Sonosite said it is seeking a variety of remedies from Butterfly, including damages related to the company's alleged "unauthorized use" of the patents, as well as manufacture, marketing, promotion, and sale of Butterfly's iQ and iQ+ POCUS scanners.
Sonosite's origins come from a grant issued in the 1990s by the U.S. Defense Advanced Research Projects Agency (DARPA) to ATL Ultrasound to develop a handheld scanner for battlefield medicine applications. That project later evolved into a standalone company that was spun off from ATL by an executive team led by Kevin Goodwin
Sonosite launched its first commercial scanner in 1998. SonoSite was later acquired by Fujifilm in a deal completed in 2012.
Fujifilm Sonosite has successfully defended its patient technology in the past. In 2006, Sonosite won a case against patent holding company Neutrino Development. SonoSite has also defended its patents against GE Healthcare.
For its part, Butterfly Network was founded in 2011 by serial entrepreneur Jonathan Rothberg, PhD, who developed next-generation DNA sequencing. The company received U.S. Food and Drug Administration clearance in 2017 for its Butterfly iQ scanner, a handheld system that sells commercially for under $2,000.
Butterfly went public in 2000 through a merger with Longview Acquisition, a special-purpose acquisition company (SPAC). In recent weeks, the company has been hit with a number of shareholder lawsuits following a decline in its stock price.
![Examples of ultrasound findings and techniques. (A) Images in a 39-year-old male patient with a mass in the left thigh. The mass is heterogeneous on the B-mode US image (compared with the patient in D) and showed increased microvascularity (superb microvascular imaging [SMI]) and shear-wave elastography (SWE) values. Undifferentiated pleomorphic sarcoma was diagnosed at biopsy (with pleomorphic rhabdomyosarcoma in surgical specimen). (B) Images in an 18-year-old male patient with a mass in the left leg. The mass is hypoechoic on the B-mode image, with no other findings suggestive of malignancy. The lesion is in contact with the cortex of the tibia, which is slightly irregular. CT revealed a doubtful anteromedial tibial erosion. The microvascular study demonstrated high vascularization, suggestive of malignancy. Periosteal Ewing sarcoma was diagnosed with both histologic and immunohistochemical confirmation. (C) Images in a 69-year-old female patient with a lump growing on the outside of the left leg. Multiple SWE examinations were performed (please note the high values obtained in the measurements, whereas the color map highlights the stiffness relative to adjacent tissues). SMI showed areas of increased vascularization to target for sampling. Undifferentiated spindle cell sarcoma was diagnosed at biopsy, with residual leiomyosarcoma in the surgical specimen after neoadjuvant therapy. (D) Images in a 56-year-old female patient with a mass in the right thigh. The mass is heterogeneous at both B-mode ultrasound (similar to patient A) and MRI (coronal T2-weighted spectral attenuated inversion recovery [SPAIR]; T1-weighted pre-contrast and postcontrast imaging), which even shows uptake after the administration of paramagnetic contrast material, which is traditionally suggestive of malignancy. Low values at SMI and elastography are suggestive of benignity. Spindle cell lipoma was diagnosed at biopsy, with atypical spindle cell lipomatous tumor in the surgical specimen.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/08/images-radiol250278fig2.APCFLSvX6p.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
